Common Contracts
2 similar Underwriting Agreement contracts by Baudax Bio, Inc., Marrone Bio Innovations Inc
1,831,631 Shares Pre-Funded Warrants to Purchase 1,677,141 Shares Common Warrants to Purchase 3,508,772 Shares BAUDAX BIO, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 1st, 2022 • Baudax Bio, Inc. • Services-misc health & allied services, nec • New York
Baudax Bio, Inc., a Pennsylvania corporation (the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom H.C. Wainwright & Co., LLC is acting as representative (the “Representative”), (i) an aggregate of 1,831,631 shares (the “Firm Shares”) of its common stock, par value $0.01 per share (the “Common Stock”), (ii) warrants, substantially in the form of Annex A hereto (the “Pre-Funded Warrants”), to purchase an aggregate of 1,677,141 shares of Common Stock with an exercise price equal to $0.01 per share (the “Pre-Funded Warrants”), and (iii) warrants, substantially in the form of Annex A hereto (the “Common Warrants”), to purchase an aggregate of 3,508,772 shares of Common Stock with an exercise price equal to $3.25 per share (the “Firm Warrants”). In addition, the Company has granted to the Underwriters an option to purchase (i) up to an additional 526,315 shares of Common Stock (the “Optional Shares”), and/or (ii) up to an addi
5,714,286 SHARES MARRONE BIO INNOVATIONS, INC. COMMON STOCK UNDERWRITING AGREEMENTUnderwriting Agreement • April 25th, 2017 • Marrone Bio Innovations Inc • Agricultural chemicals • New York
Marrone Bio Innovations, Inc., a Delaware corporation (the “Company”) proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule VI hereto (the “Underwriters”), for whom National Securities Corporation is acting as representative (the “Representative”), an aggregate of 5,714,286 authorized but unissued shares (the “Firm Shares”) and, at the election of the Underwriters, upon the terms and conditions stated herein, up to 857,143 additional shares (the “Additional Shares”) of Common Stock, $0.00001 par value per share (the “Common Stock”), of the Company (the Firm Shares and the Additional Shares that the Underwriters elect to purchase pursuant to Section 3 hereof being collectively called the “Securities”).
